Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia
Condition:  Chronic Lymphocytic Leukemia Interventions:  Drug: Acalabrutinib;  Procedure: Biospecimen Collection;  Procedure: Bone Marrow Aspiration;  Procedure: Bone Marrow Biopsy;  Procedure: Computed Tomography;  Procedure: Echocardiography;  Biological: Obinutuzumab;  Other: Questionnaire Administration;  Biological:  Tafasitamab Sponsors:  OHSU Knight Cancer Institute;  Oregon Health and Science University;  Incyte Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Research